Announcements Trials
Browse Landscape

Phase

Phase 2 1

Status

Active not recruiting 1

Sponsor Class

NIH 1

Study Type

Interventional 1

Sponsor

Cancer Type

Gastrointestinal 1

Conditions

Rectal Neoplasms 4Anus Neoplasms 2Neoplasms 1HIV Infections 1Colorectal Neoplasms 1Colonic Neoplasms 1Anal Canal Carcinoma 1

Interventions

Specimen Handling 2Nivolumab 2Magnetic Resonance Spectroscopy 2Etoposide 2liposomal doxorubicin 1dehydroftorafur 1carmustine, poliferprosan 20 drug combination 1cabozantinib 1Zidovudine 1X-Rays 1Vincristine 1Valganciclovir 1Sirolimus 1Sigmoidoscopy 1Sentinel Lymph Node Biopsy 1Rituximab 1Radiotherapy, Intensity-Modulated 1Proctoscopy 1Prednisone 1Peripheral Blood Stem Cell Transplantation 1Mitozytrex 1Mitomycin 1Melphalan 1Interferon-alpha 1Human Papillomavirus Recombinant Vaccine nonavalent 1Granulocyte Colony-Stimulating Factor 1Fluorouracil 1Fluorodeoxyglucose F18 1Filgrastim 1Doxorubicin 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Active not recruiting × HIV Infections × Sigmoidoscopy × Clear all
NCT04929028 2026-05-13

Therapy Adapted for High Risk and Low Risk HIV-Associated Anal Cancer

National Cancer Institute (NCI)

Phase 2 Active not recruiting
40 enrolled
Gastrointestinal

Anus Neoplasms, Rectal Neoplasms, HIV Infections

Data powered by HemOnc (CC BY 4.0) Colophon âš¡